Recombinant Mycobacterium bovis bacillus Calmette-Guérin secreting merozoite surface protein 1 (MSP1) induces protection against rodent malaria parasite infection depending on MSP1-stimulated interferon gamma and parasite-specific antibodies.
about
Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal modelInterferon-gamma responses to Plasmodium falciparum liver-stage antigen-1 and merozoite-surface protein-1 increase with age in children in a malaria holoendemic area of western KenyaA New Screen for Tuberculosis Drug Candidates Utilizing a Luciferase-Expressing Recombinant Mycobacterium bovis Bacillus Calmette-GuérenRecombinant Mycobacterium bovis BCG as an HIV vaccine vector.Protection by a recombinant Mycobacterium bovis Bacillus Calmette-Guerin vaccine expressing Shiga toxin 2 B subunit against Shiga toxin-producing Escherichia coli in mice.Vaxvec: The first web-based recombinant vaccine vector database and its data analysisRecombinant Mycobacterium bovis BCG expressing pertussis toxin subunit S1 induces protection against an intracerebral challenge with live Bordetella pertussis in mice.The use of directed evolution to create a stable and immunogenic recombinant BCG expressing a modified HIV-1 Gag antigenLinkage of exogenous T-cell epitopes to the 19-kilodalton region of Plasmodium yoelii merozoite surface protein 1 (MSP1(19)) can enhance protective immunity against malaria and modulate the immunoglobulin subclass response to MSP1(19).Plasmidic versus insertional cloning of heterologous genes in Mycobacterium bovis BCG: impact on in vivo antigen persistence and immune responsesMerozoite surface protein 1-specific immune response is protective against exoerythrocytic forms of Plasmodium yoelii.Mycobacterium-induced potentiation of type 1 immune responses and protection against malaria are host specific.Intracellular bacteria as targets and carriers for vaccination.Immunomodulatory effects of recombinant BCG expressing MSP-1C of Plasmodium falciparum on LPS- or LPS+IFN-γ-stimulated J774A.1 cellsGeneration of CD8+ T-cell responses by a recombinant nonpathogenic Mycobacterium smegmatis vaccine vector expressing human immunodeficiency virus type 1 Env.Mycobacterium bovis Bacille Calmette-Guérin as a Vaccine Vector for Global Infectious Disease ControlCloning and expression of malaria and tuberculosis epitopes in mycobacterium bovis bacille calmette-guérinRecombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses.A chimeric Plasmodium falciparum merozoite surface protein vaccine induces high titers of parasite growth inhibitory antibodiesRecombinant Mycobacterium smegmatis with a pMyong2 vector expressing Human Immunodeficiency Virus Type I Gag can induce enhanced virus-specific immune responses.The path of malaria vaccine development: challenges and perspectives.The BCG replacement vaccine VPM1002: from drawing board to clinical trial.Oral vaccination of mice against rodent malaria with recombinant Lactococcus lactis expressing MSP-1(19).Immunogenicity and in vitro protective efficacy of recombinant Mycobacterium bovis bacille Calmette Guerin (rBCG) expressing the 19 kDa merozoite surface protein-1 (MSP-1(19)) antigen of Plasmodium falciparum.Recombinant BCG vaccines: molecular features and their influence in the expression of foreign genes.Development of a Live Recombinant BCG Expressing Human Immunodeficiency Virus Type 1 (HIV-1) Gag Using a pMyong2 Vector System: Potential Use As a Novel HIV-1 Vaccine.Optimizing HIV-1-specific CD8+ T-cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors
P2860
Q24675231-D483EC02-9749-4ACD-A146-F0F2357CEA66Q24797832-0B77E2C4-B2D0-43AA-BC61-9DAF75DD5D68Q28551001-020347ED-4505-4337-9C01-4104399005E8Q30387447-9FE71C2C-28ED-4AF7-9034-D0FEC8CEE896Q30418998-D40424BA-588C-45ED-BEB2-AD0B940224E9Q30996881-11F5A723-7C2C-4A11-8367-7B5A56A200EFQ33596979-EF48F214-279A-47F2-A6F5-490AE4DBA67FQ33952259-3B6322A1-E9FA-4B91-BD1B-55E3760D8AFEQ34003924-42318D12-D2C2-4D57-90A8-12337B480353Q34116296-5017C142-D989-4038-8FB6-2F97395842D8Q34183154-D71111A1-394A-43F8-9560-51DA212E56C7Q34194659-18AA4C22-79BC-4BD5-9D50-AB648AF9CEADQ34280918-57E54326-73F9-4B6F-93B1-2402B88ADAB7Q34291036-E373A07F-21A7-4028-9067-9D69D1918974Q34353428-B375537F-919E-479C-BC22-D68D7FC6AD94Q35909944-DE94EED1-A16D-4E0B-9AFF-0ABB8D519926Q35945453-C24056E7-75D8-4A13-9C4B-0B11F7F55D51Q37191912-5F193337-AC41-4230-B6C1-56D1941A52A3Q37264673-BD871652-7EA9-4E03-9D38-B72D6879BC3FQ37704447-8782B050-4180-40DE-AF12-9B7CB8D7AFE0Q38196455-C05C42D7-4651-4EA4-8671-962A1E5AB9CBQ38202181-7C5E9A55-73D9-43C6-A24F-B019D732387CQ41955368-9D8ACB3E-753E-4FE5-AA1C-38DA5849A650Q47964774-1EB33D9B-FFEA-4D97-BBC2-A3C1567EBC83Q47988525-6C28121B-972A-4BB2-8623-2541F86D6BF2Q52595182-EDE21D97-C92F-4C91-B589-7CB2C64A878CQ57078025-D0C972A1-E9DB-4115-81C2-306A80B41464
P2860
Recombinant Mycobacterium bovis bacillus Calmette-Guérin secreting merozoite surface protein 1 (MSP1) induces protection against rodent malaria parasite infection depending on MSP1-stimulated interferon gamma and parasite-specific antibodies.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Recombinant Mycobacterium bovi ...... parasite-specific antibodies.
@ast
Recombinant Mycobacterium bovi ...... parasite-specific antibodies.
@en
type
label
Recombinant Mycobacterium bovi ...... parasite-specific antibodies.
@ast
Recombinant Mycobacterium bovi ...... parasite-specific antibodies.
@en
prefLabel
Recombinant Mycobacterium bovi ...... parasite-specific antibodies.
@ast
Recombinant Mycobacterium bovi ...... parasite-specific antibodies.
@en
P2093
P2860
P356
P1476
Recombinant Mycobacterium bovi ...... parasite-specific antibodies.
@en
P2093
P2860
P304
P356
10.1084/JEM.188.5.845
P407
P577
1998-09-01T00:00:00Z